




The SAPIEN 3 Ultra RESILIA Valve Is Designed to Further Elevate Long-Term Durability and Valve Performance^{7,9}



Advanced calcium-blocking tissue technology⁸



Taller,* textured outer skirt extended to 29 mm valve



Only Transcatheter heart valve with dry tissue storage

RESILIA tissue effectively addresses calcification, a leading cause of tissue valve failure⁷



See SAPIEN Platform long-term data at: heartvalves.com



*Compared to the SAPIEN 3 transcatheter valve.

References:

1. Leon MB, Mack MJ, Pibarot P, et al Transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years. N Engl J Med. Published on October 27, 2025.
2. Makkar R. Ten-year outcomes of the PARTNER 2 intermediate-risk studies: a propensity-matched analysis of P2S3i TAVR and P2A surgery. Presented at: TCT 2025; October 27, 2025; San Francisco, CA.
3. Leon, M. B., Smith, C. R., Mack, M. J., et al (2010). Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. The New England Journal of Medicine, 363(17), 1597–1607
4. Svensson LG. A comprehensive review of the PARTNER trial. J Thorac Cardiovasc Surg. 2013 Mar;145(3 Suppl):S11-6.
5. Edwards SAPIEN 3 TAVR delivers proven long-term benefits and valve performance, new data presented at TCT 2025. Edwards Lifesciences. Published October 27, 2025. Accessed November 7, 2025. <https://www.edwards.com/newsroom/news/2025-10-27-edwards-sapien-3-tavr-delivers-proven-long-term-be>
6. Leon, MB., Mack, MJ. Supplementary appendix to: Transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years. The New England Journal of Medicine. Published on October 27, 2025. doi: 10.1056/NEJMoa2509766
7. Beaver T, Bavaria JE, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2024;168(3):781-791.
8. De La Fuente AB, Wright GA, Olin JM, et al. Advanced integrity preservation technology reduces bioprosthesis calcification while preserving performance and safety. J Heart Valve Dis. 2015;24(1):101-109.
9. SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve System IFU

Expert opinions, advice and all other information expressed represent contributors' views and not necessarily those of Edwards Lifesciences.

Clinical data on surgical valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10 years in progress.⁷

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, PARTNER, PARTNER II, PARTNER 3, RESILIA, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra and the PARTNER design logo are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2026 Edwards Lifesciences Corporation. All rights reserved. PP-EU-11549 v1.0

Edwards Lifesciences Sàrl • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com



Edwards SAPIEN 3 Platform:

SUSTAINED

durability and valve performance




Outcomes from the PARTNER Trials:

SAPIEN 3 TAVI Demonstrates Excellent Long-Term Durability and Valve Performance Comparable to SAVR out to 7 and 10 Years^{1,2}




The PARTNER Trials: 20 Years of Advances in TAVI Evidence Generation and Care for Severe Aortic Stenosis Patients^{1,3,4}

The PARTNER 3 Trial Design¹




*Includes patients evaluable for the primary composite endpoint. Doxas not include VSS data.¹ | AT=as treated; TA=transapical; TAO=transaortic; TF=transfemoral; VSS=vital status sweep.

The PARTNER 2A and S3i Study Designs²



Mortality Outcomes With SAPIEN 3 TAVI Were Comparable to SAVR at 7 and 10 Years

The PARTNER 3 Low-Risk Trial: 7-Year Follow-Up^{*1}




*"In The PARTNER 3 Low-Risk Trial, we again see the early clinical benefit of TAVR with SAPIEN 3 over surgery, as well as excellent long-term valve performance and durability results for both therapies at 7 years, which should be reassuring to patients and their physicians."*⁵

- Martin Leon, MD

*Includes VSS data. VSS was performed by sites on patients who withdrew, were lost to follow-up, did not re-consent, or missed a visit.^{1,2} | [†] Baseline characteristics of TAVI group | STS=Society of Thoracic Surgeons.

SAPIEN 3 TAVI Demonstrated Excellent Long-Term Durability and Valve Performance at 7 and 10 Years

The PARTNER 3 Trial: AV Reintervention Rates at 7 Years¹



AV reintervention rates with the SAPIEN 3 valve were low and comparable to SAVR at both 7 and 10 years in both trials.^{1,2} With this older generation valve, the leading causes of reintervention were stenosis and PV leak.^{1,2,6}

